Search Videos by Topic or Participant
Browse by Series:

Integrating a Medical Oncologist Into Urology Practices

Panelists: Raoul S. Concepcion, MD, Urology Associates; Richard M. Harris, MD, UroPartners, LLC; Gary M. Kirsh, MD, Urology Group; Neal D. Shore, MD, Ca
Published: Friday, Apr 03, 2015
For High-Definition, Click
The CHAARTED trial studied the combination of androgen deprivation therapy (ADT) plus docetaxel therapy versus ADT alone in 790 patients diagnosed with hormone-sensitive metastatic prostate cancer. The combination resulted in a median overall survival of 57.6 months compared with 44 months in the ADT–alone arm (P = .0003).

Based on these and similar results, many urology practices are providing or considering providing intravenous chemotherapy therapy on-site for their cancer patients. In order to accomplish this, many urology practices will need to have a medical oncologist available on-site a few times a month to provide chemotherapy administration services, Gary M. Kirsh, MD, suggests. A number of urology groups around the country are incorporating medical oncology services.

It could be challenging to fully engage a medical oncologist in a urology practice, Sanford J. Siegel, MD, notes. However, having a medical oncologist on-site is in line with the integrated care model, and aids in further educating cancer patients about their options.
Slider Left
Slider Right
For High-Definition, Click
The CHAARTED trial studied the combination of androgen deprivation therapy (ADT) plus docetaxel therapy versus ADT alone in 790 patients diagnosed with hormone-sensitive metastatic prostate cancer. The combination resulted in a median overall survival of 57.6 months compared with 44 months in the ADT–alone arm (P = .0003).

Based on these and similar results, many urology practices are providing or considering providing intravenous chemotherapy therapy on-site for their cancer patients. In order to accomplish this, many urology practices will need to have a medical oncologist available on-site a few times a month to provide chemotherapy administration services, Gary M. Kirsh, MD, suggests. A number of urology groups around the country are incorporating medical oncology services.

It could be challenging to fully engage a medical oncologist in a urology practice, Sanford J. Siegel, MD, notes. However, having a medical oncologist on-site is in line with the integrated care model, and aids in further educating cancer patients about their options.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x